Here are four lab buildings that offer cutting-edge, flexibly designed research facilities in addition to connections to the broader community and a lively mix of services and activities at the workplace and beyond. Element Labs, (Madison), Kendall Square Initiative (Cambridge), Simpson Querrey Biomedical Research Center...
Agilent Technologies, Inc. and Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. ...
Exact Sciences Corp. today announced that the National Cancer Institute (NCI) has selected the company's testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, one of the NCI-funded precision medicine initiatives....
A consortium of 15 public and private partners has been formed to advance an economic development strategy aimed at bolstering Wisconsin’s leadership in personalized medicine and biohealth technology....
Laura Strong is vice president of strategy and health care for DataChat. “We are an entrepreneur-driven organization,” Strong said. “Our board is all driven by entrepreneurs; the events are all created by entrepreneurs."...
Exact Sciences plans to seek approval soon of an updated Cologuard stool-based colon cancer screening test and launch a blood test to detect cancer that can linger after surgery....
In a memo delivered last week to all members of the state Legislature, the board members are urging action by this fall on the $347 million project. They wrote the effort is “vital to the entire state, especially its business and research communities, for many...
Ayla Annac, president and CEO of InvivoSciences highlights a “severe unmet need” for drugs to effectively treat patients for a specific form of heart failure using precision medicine....
Investments in young, Wisconsin-based companies by angel and venture capitalists and other equity investors totaled $640.2 million in 2022, far from the previous year’s total of $868.8 million but still the second-highest investment total on the books....
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study. "Cologuard is a groundbreaking innovation in non-invasive cancer detection. Next-generation Cologuard will set a new performance standard," said Kevin Conroy, chairman and CEO...